News | March 26, 2014

Data Show Seno’s Imagio May Eliminate Need for a Breast Biopsy

Two separate analyses of feasibility study data presented at the European Congress of Radiology 2014

March 26, 2014 — Seno Medical Instruments Inc. presented two analyses of outcomes from a U.S. feasibility study of its investigational Imagio breast-imaging device at the annual meeting of the European Congress of Radiology 2014.

The first statistical analysis is of the feasibility study data (Abstract C-0926) and suggests that information from Imagio may have the potential to achieve clinically meaningful sensitivity and specificity for breast cancer beyond those achievable with traditional, standalone diagnostic ultrasound. This will be verified in the ongoing U.S. pivotal study, which has already enrolled more than half of the 2,000 subject target. Imagio may be a useful tool to help physicians reduce the need for breast biopsy in patients with benign but suspicious appearing breast masses on conventional diagnostic breast ultrasound.

The second statistical analysis is of pre-defined histopathology findings relative to the specific features of benign and malignant lesions. This information was captured in the Imagio opto-acoustic images during the feasibility study. It suggests that Imagio may have the potential to provide additional information that could help clinicians grade the aggressiveness of cancerous breast tumors during the imaging phase of a woman's diagnostic work-up, which will also be verified in the ongoing pivotal study.

Separate analysis of the feasibility data showed that OA findings could potentially correlate with molecular subtypes of breast cancer (Abstract C-1528). Imagio fuses an imaging technology based on light-in and sound-out called "opto-acoustics" with traditional ultrasound. The opto-acoustic images provide a unique blood map in and around suspicious breast masses. Unlike other imaging modalities, Imagio doesn't expose patients to potentially harmful ionizing radiation (X-rays) or injectable contrast agents.

For more information: www.SenoMedical.com

Related Content

Joseph J. Cappello Named Executive Director of Are You Dense Nonprofits
News | Breast Density | February 20, 2019
The boards of Are You Dense Inc. and Are You Dense Advocacy Inc., founded by the late Nancy M. Cappello, Ph.D.,...
Congress Directs FDA to Establish Federal Breast Density Inform Standard
News | Breast Density | February 19, 2019 | Jeff Zagoudis, Associate Editor
As part of a federal spending bill passed late Friday, Congress directed the U.S. Food and Drug Administration (FDA) to...
Densitas Enters Partnership Agreement With TeleMammography Specialists
News | Breast Density | February 14, 2019
Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography...
Hologic Launches Unifi Analytics Business Intelligence Tool
Technology | Analytics Software | February 12, 2019
Hologic Inc. announced the U.S. launch of Unifi Analytics, a business intelligence tool that allows healthcare...
Mount Sinai's Digital 3-D Mammography Van Rolls Into New York City
News | Mammography | February 11, 2019
Mount Sinai Hospital recently launched the Mount Sinai Mobile Mammography Program (MMP), bringing essential breast...
breast density cancer awareness
News | Breast Density | February 08, 2019
Governor Michelle Lujan Grisham has signed breast density inform bill, ...
Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support
News | Clinical Decision Support | February 05, 2019
Siemens Healthineers showcased the new planned artificial intelligence (AI)-based features with its mammography reading...
 Volpara Solutions Launches Next-Generation VolparaDensity Software to Support SmartCurve Paddles
Technology | Breast Density | January 31, 2019
Volpara Solutions Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for new technologies used in...
QTbreasthealth Opens New Breast Ultrasound Imaging Center in Grand Rapids
News | Ultrasound Women's Health | January 30, 2019
January 30, 2019 — QTbreasthealth launched a center in Grand Rapids, Mich., featuring its quantitative transmission
Traditional mammography continues to be the gold standard for breast cancer screening technologies. However, use of 3-D breast tomosynthesis is growing rapidly.

Traditional mammography continues to be the gold standard for breast cancer screening technologies. However, use of 3-D breast tomosynthesis is growing rapidly.

Feature | Breast Imaging | January 30, 2019 | By Jeff Zagoudis
The importance of early detection of...